This invention relates to the treatment of cancer, particularly to methods of treating head and neck cancer. The invention provides for the use of modulators of the renin-angiotensin system, such as ss-blockers, including Propranolol, for diagnosing and treating cancers, including head and neck cancers.

A pharmaceutical preparation for oral administration comprising a combination of an ACE inhibitor such as Ramipril, benzapril or a pharmaceutically acceptable salt thereof, and a non selective Beta-blocker such as Carvedilol, propranolol etc, or a pharmaceutically acceptable salt thereof, wherein the ACE inhibitor compound is in immediate release form, the beta-blocker compound is in immediate release form and, the combination is in a solid fixed-unit dosage form such as a capsule or a tablet.

Composicion farmacéutica de administracion oral que contiene ésteres alquílicos de ácidos grasos poliinsaturados (PUFA) y principios activos farmacéuticos betabloqueantes para el tratamiento y/o prevencion de enfermedades cardiovasculares. Reivindicacion 2: Composicion farmacéutica segun la reivindicacion 1 donde los ácidos grasos poliinsaturados de dichos ésteres alquílicos pertenecen a la serie omega-3. Reivindicacion 4: Composicion farmacéutica segun la reivindicacion 1 donde el radical alqui...

A process for making an oral dosage form of a pharmaceutical composition comprising the steps of: (a) combining a therapeutic compound selected from the group consisting of metoclopramide and propantheline bromide

The present invention provides an ophthalmic composition comprising a hyperbranched polymer. The ophthalmic compositions may also comprise carbonic anhydrase inhibitors, wherein the hyperbranched polymer increases the aqueous solubility of the carbonic anhydrase inhibitor, and increases corneal permeation of the active agent. The ophthalmic compositions may also comprise non-ionic surfactants, such as polysorbate, hydroxypropyl methyl cellulose or hydroxyethyl cellulose, and beta-blockers, such ...

The present invention provides an ophthalmic composition comprising a hyperbranched polyester. The ophthalmic compositions may also comprise carbonic anhydrase inhibitors, wherein the hyperbranched polyester increases the aqueous solubility of the carbonic anhydrase inhibitor, and increases corneal permeation of the active agent. The ophthalmic compositions may also comprise non-ionic surfactants, such as PEG, Polysorbate, HPMC or HEC, and beta-blockers,such as Carteolol, Levobunolol, Betaxolol,...

The disclosure provides a pharmaceutical composition for treating social anxiety performance anxiety and social phobia comprising a therapeutic amount for die treatment of a patient of a &bgr;-adrenergic receptor antagonist an anti-diarrheal compound and an optional anticholinergic compound. The &bgr;-adrenergic receptor antagonist may be the lipophilic &bgr;-blocker propranolol HCl the anti-diarrheal compound may be the opioid diphenoxylate HCl and the optional anticholinergic compound may be a...